J&J mid-stage trial for lung cancer drug Rybrevant hits main goal

Johnson & Johnson (NYSE:JNJ) announced that a Phase 2 open-label trial for its lung cancer therapy Rybrevant reached the primary endpoint related to infusion-related reactions following corticosteroid therapy dexamethasone.

Gilberto Lopes, a medical oncologist who presented the trial data at a medical event on Tuesday, said the results offer insights into how patient experience can be improved when Rybrevant is prescribed.

According to J&J (JNJ), the lung cancer patients who received 8 mg dexamethasone two days before the first Rybrevant infusion met the primary endpoint, indicating a threefold decline in the incidence of IRR compared to standard management.

Patients on dexamethasone demonstrated an all-grades IRR rate of 22.5% at Cycle 1 Day 1, compared to 67.4% associated with the standard management of IRR linked to intravenous Rybrevant based on historical data.

“This study shows us that an easily accessible approach of an increased dose regimen of dexamethasone as a pre-treatment prophylaxis can potentially help lower IRRs,” Lopes added.

More clinical studies are underway to evaluate prophylactic strategies to cut IRR incidence linked to IV Rybrevant.